Loss of TLR9 expression in breast cancer tumour cells and its role in the cell cycle.
Sible, E.; Weitsman, G.; Amouya, S.; Roblot, G.; Marotel, M.; Pescarmona, R.; Bendriss-Vermare, N.; Gillet, C.; Walzer, T.; Ceesay, A.; Michallet, M.-C.; Caux, C.; Cosset, F.-L.; Al-alem, U.; Ng, T.; Hasan, U. A.
Show abstract
Toll-like receptor 9 (TLR9), primarily expressed in human dendritic and B cells, recognizes double-stranded DNA motifs from pathogens, initiating an inflammatory response. Recent studies have revealed TLR9s involvement beyond its conventional role in immune response, notably during the tumorigenesis of various cancers such as head and neck, cervical, and ovarian cancers. Here we show by immunohistochemistry analysis demonstrated significantly lower TLR9 levels in breast cancer tumors compared to normal breast tissue epithelium. Similarly, TLR9 downregulation was also observed in several transformed breast cancer cell lines versus untransformed breast epithelial cell lines. Furthermore, overexpression of TLR9 led to reduced proliferation potential of breast cancer cell associated with activation of senescence as was evident by upregulation of proinflammatory cytokine IL-6, chemokines IL-8 and CXCL1; and growth factor GM-CSF. These findings support TLR9s regulatory role in mitigating breast cancer and highlight its critical connection between the inflammatory response and tumor immunity.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.